CBR-470-1 is an inhibitor of the glycolytic enzyme phosphoglycerate kinase 1 (PGK1) . CBR-470-1 is also a non-covalent Nrf2 activator. CBR-470-1 protects SH-SY5Y neuronal cells against MPP + -induced cytotoxicity through activation of the Keap1-Nrf2 cascade In Vitro CBR-470-1 (0.01-10 μM; 24 h) has an EC 50 of 962 nM in ARE-LUC reporter assay of IMR32 cells. CBR-470-1 (0.5-20 μM; 1-24 h) results in a dose- and time-dependent accumulation of Nrf2 protein in IMR32 cells. CBR-470-1 (10 μM; 4 h) activates Nrf2 signaling cascade in SH-SY5Y cells. CBR-470-1 (10 μM; 2 h) inhibits MPP + -induced oxidative injury in SH-SY5Y neuronal cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: IMR32 cells Concentration: 0.5, 1, 5, 10, 20 μM Incubation Time: 1, 2, 4, 8, 24 h Result: Increased the Nrf2 protein in a dose- and time-dependent manner. Increased both mRNA and protein levels of the Nrf2-responsive genes NQO1 and HMOX1 . Form:Solid IC50& Target:Keap1-Nrf2